Indasi Lifescience Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Indasi Lifescience Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $2.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Indasi Lifescience Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $2.4M Trade | TransData Nexus

Indasi Lifescience Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $2.4M Total Trade · DGFT Verified

Indasi Lifescience Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.4M across 2 products in 2 therapeutic categories. Based on 69 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Artesunate ($2.3M), Fosfomycin ($122.7K), .

Indasi Lifescience Private Limited — Export Portfolio & Destination Treemap

Indasi Lifescience Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Indasi Lifescience Private Limited? — Company Overview & Market Position

Indasi Lifescience Private Limited, established on March 9, 2011, is a privately held pharmaceutical company headquartered in Daman, India. The company is registered under the Corporate Identification Number (CIN) U24230DD2011PTC004692. With an authorized capital of ₹2.10 crore and a paid-up capital of ₹1.81 crore, Indasi Lifescience operates as a non-government entity.

The company's manufacturing facility is located at Plot No. 73 to 76, Silver Industrial Estate, Bhimpore, Daman 396210, Daman and Diu, India. Indasi Lifescience specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is committed to adhering to international quality standards, as evidenced by its WHO-GMP certification.

What Does Indasi Lifescience Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Artesunate$2.3M 2Fosfomycin

Product Portfolio — Top 2 by Export Value

Indasi Lifescience Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Artesunate	Antimalarial & Antiparasitic	$2.3M	63	1.3%	8
2	Fosfomycin	Advanced Antibiotics	$122.7K	6	1.0%	6

Indasi Lifescience Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $2.4M. The top category is Antimalarial & Antiparasitic (94.9% of portfolio), followed by Advanced Antibiotics (5.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Indasi Lifescience Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Indasi Lifescience's manufacturing plant is situated in Daman, India, within the Silver Industrial Estate. The facility is WHO-GMP certified, ensuring compliance with international quality standards. It is equipped with modern infrastructure capable of producing various pharmaceutical formulations, including sterile lyophilized products, freeze-dried products, and non-sterile active pharmaceutical ingredients (APIs). The plant's design emphasizes efficiency and quality, supporting both domestic and international markets.

3Key Leadership

The leadership team at Indasi Lifescience comprises:

Mr. Hasmukhbhai Natvarlal Patel: Director
Mr. Ravindrakumar Hiralal Singh: Director
Mr. Vikash Ravindra Singh: Whole-Time Director

These individuals have been instrumental in steering the company's strategic direction and operational excellence since its inception.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Indasi Lifescience Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Indasi Lifescience has made significant strides in regulated markets, particularly in Africa, Latin America, Southeast Asia, and other regions. The company's WHO-GMP certification facilitates access to these markets, as it is recognized by regulatory authorities in these regions. This certification underscores Indasi Lifescience's commitment to maintaining high-quality manufacturing standards, which is crucial for market acceptance and growth in these areas.

2Emerging Markets

Indasi Lifescience has strategically positioned itself to penetrate emerging markets in Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its credibility and facilitates smoother entry into these regions. By aligning with international quality standards, Indasi Lifescience aims to meet the growing pharmaceutical needs in these markets, thereby expanding its global footprint.

3Geographic Strategy

Indasi Lifescience's geographic strategy focuses on diversification, targeting both domestic and international markets. The company's WHO-GMP certification enables it to access a wide range of markets, reducing concentration risk. By expanding its presence in emerging markets, Indasi Lifescience aims to achieve sustainable growth and mitigate risks associated with over-reliance on a single market.

Indasi Lifescience Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available information, Indasi Lifescience has not listed any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company has not been subject to any FDA inspections, Form 483 observations, warning letters, or import alerts. This indicates that Indasi Lifescience has not sought approval or engaged in activities requiring FDA oversight.

2WHO & EU GMP

Indasi Lifescience holds WHO-GMP certification, affirming its compliance with international manufacturing standards. This certification is recognized by the World Health Organization and is essential for accessing various global markets. However, there is no specific information available regarding EU GMP certification or EDQM status for the company.

3CDSCO & Indian Regulatory

Indasi Lifescience operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from the state drug controller, ensuring compliance with national pharmaceutical regulations. Additionally, Indasi Lifescience has obtained export No Objection Certificates (NOCs), facilitating its export activities.

Indasi Lifescience Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Indasi Lifescience operates in a competitive pharmaceutical industry, facing competition from both domestic and international companies. While specific competitors are not identified in the available information, the company's WHO-GMP certification and diverse product portfolio position it favorably in the market. The company's focus on quality and compliance with international standards enhances its competitiveness.

2Key Differentiators

Indasi Lifescience's key differentiators include its WHO-GMP certification, which underscores its commitment to quality and international standards. The company's diverse product portfolio, encompassing ampoules, dry powder formulations, and lyophilized and liquid products, allows it to cater to a wide range of therapeutic needs. Additionally, the leadership team's experience and strategic direction contribute to the company's competitive edge.

3Strategic Position

Indasi Lifescience's current strategic direction focuses on expanding its presence in both domestic and international markets. The company's WHO-GMP certification and diverse product offerings enable it to cater to a broad spectrum of therapeutic areas. Looking ahead, Indasi Lifescience aims to strengthen its position in emerging markets and explore opportunities in generics, specialty pharmaceuticals, and contract development and manufacturing organizations (CDMO) services.

Buyer Due Diligence Brief — Evaluating Indasi Lifescience Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Indasi Lifescience has demonstrated a consistent track record in manufacturing and exporting pharmaceutical formulations. The company's WHO-GMP certification and adherence to international quality standards reflect its reliability as a supplier. While specific export volumes and consistency metrics are not detailed in the available information, the company's strategic focus on quality and compliance suggests a strong foundation for reliable supply chain operations.

2Certifications to Verify

Importers should verify the following certifications when considering Indasi Lifescience as a supplier:

WHO-GMP Certification: Confirms compliance with international manufacturing standards.

FDA Drug License: Indicates approval for manufacturing and exporting pharmaceutical products to the United States.

EU GMP Certification: Validates adherence to European Union manufacturing standards.

Frequently Asked Questions — Indasi Lifescience Private Limited

How many pharmaceutical products does Indasi Lifescience Private Limited export from India?

Indasi Lifescience Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Artesunate ($2.3M), Fosfomycin ($122.7K). Total export value is $2.4M.

What is Indasi Lifescience Private Limited's total pharmaceutical export value?

Indasi Lifescience Private Limited's total pharmaceutical export value is $2.4M, based on 69 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Indasi Lifescience Private Limited cover?

Indasi Lifescience Private Limited exports across 2 therapeutic categories. The largest are Antimalarial & Antiparasitic (94.9%, 1 products), Advanced Antibiotics (5.1%, 1 products).

Get Full Indasi Lifescience Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.